Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903543 | 0.82 | PARP1 (0.36) | CCNCCDK8METAP2 | |
| SCHEMBL20244063 | 0.77 | ESR1 (0.33) | ESR1THRATHRB | |
| SCHEMBL18409211 | 0.77 | ESR1 (0.33) | ESR1THRATHRB | |
| SCHEMBL20109740 | 0.76 | CCNC (0.36) | CCNCCDK8PTK2B | |
| SCHEMBL4577378 | 0.74 | MAPT (0.41) | CCNCCDK8METAP2 | |
| SCHEMBL21249900 | 0.73 | ESR1 (0.38) | ESR1THRATHRB | |
| SCHEMBL7904180 | 0.73 | CA1 (0.42) | CCNCCDK8 | |
| SCHEMBL19386409 | 0.70 | AHR (0.51) | — | |
| SCHEMBL21377067 | 0.69 | TDP2 (0.36) | CCNCCDK8METAP2 | |
| SCHEMBL15661473 | 0.69 | CA2 (0.42) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | CCNC 997/4885CDK8 1138/4885ESR1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.